Given the high risk of infection in patients with MM, the immune toxicity of many of the agents used to treat the disease and the various mechanisms by which these agents reduce neutrophil count, we wished to gain a better understanding of the incidence of neutropenia in the treatment of MM and the use of G-CSF prophylaxis. The gene discussed is CSF3; the disease is Miyoshi myopathy.